title: Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS).
abstract: OBJECTIVE
  The objective of the study was to assess longitudinal effects of different osteoporosis treatments on TBS and aBMD at lumbar spine.
  
  
  METHODS
  We analyzed 390 patients (men: 72; women: 318; age>40 years; mean follow-up of 20 months and BMI<37 kg/m(2)). We stratified the cohort by treatments: Naive of treatment (Naive, n=67), Calcium and Vitamin D (CaVitD, n=87), Testosterone (Te, n=36), Alendronate (AL, n=88), Risedronate (Ri, n=39), Denosumab (Dmb, n=43) and Teriparatide (PTH, n=30). The follow-up changes from baseline were normalized at 24 months.
  
  
  RESULTS
  After 24 months, Naive group TBS decreased by 3.1% (p<0.05) whereas a non-significant increase was observed for spine aBMD (Δ=+0.5%). Compared to the Naive group, significant improvement (p<0.05) was observed in both TBS and aBMD for Te, AL, Ri, Dmb and PTH groups and in the CaVitD group for TBS. At the end of the follow-up, significant improvement have been observed for aBMD in Te (+4.4%), AL (+4.1%), Ri (+4.8), D (+8.8%) and PTH (+8.8%) groups. Significant improvement was observed only in the AL (+1.4%), Dmb (+2.8%) and PTH (+3.6%) groups for TBS.
  
  
  CONCLUSIONS
  As expected, TBS of Naive subjects decreased with age. As expected a TBS preservation has been observed under AL and Ri. Te and CaVitD effects on TBS were evaluated for the first time: a similar preservation effect has been observed. A significant TBS increase was observed under Denosumab and PTH. TBS could be a useful tool to monitor treatment effects.
authors.affiliation: Cetir Grup Mèdic, Barcelona, Spain; Red Temática de Investigación cooperativa en Envejecimiento y Fragilidad - RETICEF, Instituto Carlos III, Barcelona, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Di Gregorio
authors.affiliation: Cetir Grup Mèdic, Barcelona, Spain; Red Temática de Investigación cooperativa en Envejecimiento y Fragilidad - RETICEF, Instituto Carlos III, Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Del Rio
authors.affiliation: Department of Urology, Hospital Universitari de Bellvitge - L'Hospitalet, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Rodriguez-Tolra
authors.affiliation: Cetir Grup Mèdic, Barcelona, Spain.
authors.forename: E
authors.initials: E
authors.lastname: Bonel
authors.affiliation: Cetir Grup Mèdic, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: García
authors.affiliation: Med-Imaps, R&D Department, Merignac, France. Electronic address: rwinzenrieth@medimapsgroup.com.
authors.forename: R
authors.initials: R
authors.lastname: Winzenrieth
mesh_terms: D015502:Absorptiometry, Photon; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use*; D000069448:Denosumab / Q000627:therapeutic use; D019587:Dietary Supplements; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D000068296:Risedronic Acid / Q000627:therapeutic use; D019379:Teriparatide / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use*; D014807:Vitamin D / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D019379:Teriparatide; D014807:Vitamin D; D013739:Testosterone; D000069448:Denosumab; D000068296:Risedronic Acid; D002118:Calcium; D019386:Alendronate
keywords: Bone microarchitectural texture; Bone mineral density; Osteoporosis treatments; TBS (trabecular bone score)